Lexology December 20, 2024
McDermott Will & Emery

On December 3, 2024, the US Food and Drug Administration (FDA) published final guidance titled, Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions.

The guidance finalizes core concepts of predetermined change control plans (PCCPs), which manufacturers of artificial intelligence (AI)-enabled medical devices can leverage to avoid having to create new marketing submissions each time they wish to significantly modify their devices following 510(k) clearance, de novo authorization, or premarket approval.

In Depth

Manufacturers are generally required to submit new marketing applications to the FDA for review when a software modification could significantly alter that device’s safety and effectiveness. PCCPs are supplemental documentation that manufacturers of medical devices may include as part of typical...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Medical Devices, Technology
Related Articles:
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
STAT+: 3 key issues to watch at the FDA as Trump takes office
FDA's Digital Health Advisory Committee Discusses Total Product Lifecycle Considerations for GenAI-Enabled Devices
Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug
FDA's Final Guidance Provides Practical Approach for AI-Enabled Devices Implementing Post-Market Modifications

Share This Article